MedTrace Logo

Exendin PET/CT for Imaging of Paragangliomas

NCT05418907 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-12-08

No results posted yet for this study

Summary

Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging targets. Investigators aim to evaluate the glucagon-like peptide 1 receptor (GLP-1R) as a novel target for molecular imaging of PGLs. For this purpose investigators will use the tracer 68Ga-NODAGA-exendin 4 for positron emission tomography/computed tomography (PET/CT) imaging.

Conditions

  • Paraganglioma

Interventions

RADIATION

68Ga-NODAGA-exendin-4 PET/CT

PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05418907 on ClinicalTrials.gov